{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:25:02Z","timestamp":1785450302865,"version":"3.56.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"am","delay-in-days":402,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.neurol.2021.12.005","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T22:24:51Z","timestamp":1641939891000},"page":"74-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["New onset refractory status epilepticus: State of the art"],"prefix":"10.1016","volume":"178","author":[{"given":"B.","family":"P\u00e9rin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Szurhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2021.12.005_bib0390","doi-asserted-by":"crossref","first-page":"417","DOI":"10.47102\/annals-acadmedsg.V34N7p417","article-title":"The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity","volume":"34","author":"Wilder-Smith","year":"2005","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.neurol.2021.12.005_bib0395","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1528-1167.2010.02535.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood","volume":"51","author":"van Baalen","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0400","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/brain\/84.4.680","article-title":"The acute encephalopathies of obscure origin in infants and children","volume":"84","author":"Lyon","year":"1961","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0405","first-page":"88","article-title":"De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases","volume":"103","author":"Van Lierde","year":"2003","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.neurol.2021.12.005_bib0410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1059-1311(02)00340-0","article-title":"Idiopathic catastrophic epileptic encephalopathy presenting with acute onset intractable status","volume":"12","author":"Baxter","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2021.12.005_bib0415","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2006.01.002","article-title":"Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis","volume":"69","author":"Mikaeloff","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2021.12.005_bib0420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1600-0404.2009.01198.x","article-title":"Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis","volume":"121","author":"Sakuma","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2021.12.005_bib0425","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1167.2012.03517.x","article-title":"FIRES and NORSE are distinct entities","volume":"53","author":"K\u00f6rtvelyessy","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0430","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/j.1528-1167.2011.03293.x","article-title":"AERRPS, DESC, NORSE, FIRES: multi-labeling or distinct epileptic entities?","volume":"52","author":"Ismail","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0435","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0440","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/dmcn.14553","article-title":"New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome","volume":"62","author":"Specchio","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0445","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0000000000001940","article-title":"New-onset refractory status epilepticus: etiology, clinical features, and outcome","volume":"85","author":"Gaspard","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0450","doi-asserted-by":"crossref","first-page":"e2280","DOI":"10.1212\/WNL.0000000000010787","article-title":"New-onset super-refractory status epilepticus: a case series of 26 patients","volume":"95","author":"Matthews","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0455","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.09.018","article-title":"New onset refractory status epilepticus (NORSE)","volume":"68","author":"Sculier","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2021.12.005_bib0460","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/epi.14022","article-title":"New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives","volume":"59","author":"Gaspard","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0465","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1212\/WNL.0000000000007322","article-title":"New onset refractory status epilepticus research: what is on the horizon?","volume":"92","author":"Gofton","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0470","article-title":"Unraveling the enigma of new-onset refractory status epilepticus: a systematic review of aetiologies","author":"Lattanzi","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0475","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/epi4.12113","article-title":"Jamestown Canyon encephalitis with NORSE and electrographic response to ribavirin: a case report","volume":"3","author":"Savard","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neurol.2021.12.005_bib0480","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3988\/jcn.2020.16.4.519","article-title":"Clinical approach to autoimmune epilepsy","volume":"16","author":"Jang","year":"2020","journal-title":"J Clin Neurol Seoul Korea"},{"key":"10.1016\/j.neurol.2021.12.005_bib0485","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00415-021-10468-y","article-title":"Intravenous immunoglobulin response in new-onset refractory status epilepticus (NORSE) COVID-19 adult patients","volume":"268","author":"Manganotti","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0490","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s10072-021-05239-6","article-title":"COVID-19-related refractory status epilepticus with the presence of SARS-CoV-2 (RNA) in the CSF: a case report","volume":"42","author":"Karvigh","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2021.12.005_bib0495","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10072-020-04846-z","article-title":"New-onset refractory status epilepticus (NORSE) in post SARS-CoV-2 autoimmune encephalitis: a case report","volume":"42","author":"Dono","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2021.12.005_bib0500","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2021.12.005_bib0505","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1212\/WNL.0000000000000131","article-title":"Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men","volume":"82","author":"Titulaer","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0510","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cnp.2017.06.003","article-title":"Limbic and new onset refractory tonic status epilepticus (NORSE) in anti-NMDAR encephalitis","volume":"2","author":"Kaplan","year":"2017","journal-title":"Clin Neurophysiol Pract"},{"key":"10.1016\/j.neurol.2021.12.005_bib0515","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0520","doi-asserted-by":"crossref","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","article-title":"Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis","volume":"92","author":"de Bruijn","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0525","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1212\/WNL.0000000000008785","article-title":"Hashimoto encephalopathy in the 21st century","volume":"94","author":"Mattozzi","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0530","first-page":"676358","article-title":"New onset refractory status epilepticus as an unusual presentation of a suspected organophosphate poisoning","volume":"2014","author":"Waheed","year":"2014","journal-title":"Case Rep Emerg Med"},{"key":"10.1016\/j.neurol.2021.12.005_bib0535","article-title":"A spicy status: synthetic cannabinoid (spice) use and new-onset refractory status epilepticus\u2014A case report and review of the literature","volume":"5","author":"Babi","year":"2017","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.neurol.2021.12.005_bib0540","doi-asserted-by":"crossref","first-page":"e2280","DOI":"10.1212\/WNL.0000000000010787","article-title":"New-onset super-refractory status epilepticus: A case series of 26 patients","volume":"95","author":"Matthews","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0545","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1212\/NXI.0000000000000396","article-title":"Cryptogenic NORSE: its distinctive clinical features and response to immunotherapy","volume":"4","author":"Iizuka","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2021.12.005_bib0550","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clinph.2018.10.017","article-title":"EEG analysis in anti-NMDA receptor encephalitis: description of typical patterns","volume":"130","author":"Jeannin-Mayer","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0555","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/epi.13801","article-title":"Early ictal and interictal patterns in FIRES: the sparks before the blaze","volume":"58","author":"Farias-Moeller","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0560","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/epi.16620","article-title":"The timelines of MRI findings related to outcomes in adult patients with new-onset refractory status epilepticus","volume":"61","author":"Kim","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0565","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2019.12.002","article-title":"New-onset refractory status epilepticus: a retrospective cohort study","volume":"74","author":"Gugger","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2021.12.005_bib0570","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/epi.14684","article-title":"The spectrum of neuroimaging findings in febrile infection-related epilepsy syndrome (FIRES): a literature review","volume":"60","author":"Culleton","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0575","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/j.1528-1167.2011.03250.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children","volume":"52","author":"Kramer","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0580","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eplepsyres.2017.12.008","article-title":"Cerebrospinal fluid findings in non-infectious status epilepticus","volume":"140","author":"Malter","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.neurol.2021.12.005_bib0585","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neurol.2019.12.010","article-title":"Etiological assessment of status epilepticus","volume":"176","author":"Valton","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.12.005_bib0600","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.seizure.2012.12.016","article-title":"Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy","volume":"22","author":"Gall","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2021.12.005_bib0605","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MEJ.0000000000000857","article-title":"Guidelines for the management of status epilepticus","volume":"28","author":"Outin","year":"2021","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.neurol.2021.12.005_bib0610","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","article-title":"The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol","volume":"134","author":"Shorvon","year":"2011","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","article-title":"Guidelines for the evaluation and management of status epilepticus","volume":"17","author":"Brophy","year":"2012","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.neurol.2021.12.005_bib0620","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1468-1331.2009.02917.x","article-title":"EFNS guideline on the management of status epilepticus in adults","volume":"17","author":"Meierkord","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0625","first-page":"5","article-title":"Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis","volume":"48","author":"van Baalen","year":"2017","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.neurol.2021.12.005_bib0630","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","article-title":"Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multi-center study","volume":"54","author":"Gaspard","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0635","doi-asserted-by":"crossref","first-page":"e2286","DOI":"10.1212\/WNL.0000000000010611","article-title":"Ketamine to treat super-refractory status epilepticus","volume":"95","author":"Alkhachroum","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0640","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neucli.2014.11.003","article-title":"Continuous EEG monitoring in adults in the Intensive Care Unit (ICU)","volume":"45","author":"Andr\u00e9-Obadia","year":"2015","journal-title":"Neurophysiol Clin Clin Neurophysiol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0645","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12028-016-0312-4","article-title":"A practical approach to ketogenic diet in the pediatric intensive care unit for super-refractory status epilepticus","volume":"26","author":"Farias-Moeller","year":"2017","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.neurol.2021.12.005_bib0650","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1111\/j.1528-1167.2010.02703.x","article-title":"Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES)","volume":"51","author":"Nabbout","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neurol.2021.12.005_bib0655","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0000000000000151","article-title":"Ketogenic diet for adults in super-refractory status epilepticus","volume":"82","author":"Thakur","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0660","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0665","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11940-013-0252-7","article-title":"Autoimmune status epilepticus","volume":"15","author":"Lopinto-Khoury","year":"2013","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0670","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yebeh.2015.04.054","article-title":"New-onset refractory status epilepticus (NORSE)\u2014The potential role for immunotherapy","volume":"47","author":"Khawaja","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.neurol.2021.12.005_bib0675","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617722347","article-title":"Treatment strategies for autoimmune encephalitis","volume":"11","author":"Shin","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2021.12.005_bib0680","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2012.09.011","article-title":"Plasma exchange in cryptogenic new onset refractory status epilepticus","volume":"22","author":"Li","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.neurol.2021.12.005_bib0685","doi-asserted-by":"crossref","first-page":"e012356","DOI":"10.1136\/bmjopen-2016-012356","article-title":"ImmunoglobuliN in the Treatment of Encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial","volume":"6","author":"Iro","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2021.12.005_bib0690","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bj.2020.03.009","article-title":"Neurocritical care and target immunotherapy for febrile infection-related epilepsy syndrome","volume":"43","author":"Sakuma","year":"2020","journal-title":"Biomed J"},{"key":"10.1016\/j.neurol.2021.12.005_bib0695","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/epi4.12447","article-title":"Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): a report from FIRES workshop","volume":"6","author":"Koh","year":"2021","journal-title":"Epilepsi Open"},{"key":"10.1016\/j.neurol.2021.12.005_bib0700","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0705","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","article-title":"Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort","volume":"86","author":"Lee","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.12.005_bib0710","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.braindev.2016.02.006","article-title":"Acute encephalitis with refractory, repetitive partial seizures: pathological findings and a new therapeutic approach using tacrolimus","volume":"38","author":"Sato","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.neurol.2021.12.005_bib0715","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.3390\/ijms22126282","article-title":"Towards a treatment for neuroinflammation in epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a potential treatment in intractable epilepsy","volume":"22","author":"Yamanaka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2021.12.005_bib0720","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with Anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0725","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/acn3.51229","article-title":"Anakinra usage in febrile infection related epilepsy syndrome: an international cohort","volume":"7","author":"Lai","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0730","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.neurol.2021.12.005_bib0735","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.25374","article-title":"Tocilizumab treatment for new onset refractory status epilepticus","volume":"84","author":"Jun","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0740","doi-asserted-by":"crossref","first-page":"100431","DOI":"10.1016\/j.ebr.2021.100431","article-title":"Resolution of cryptogenic new onset refractory status epilepticus with tocilizumab","volume":"15","author":"Donnelly","year":"2021","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.neurol.2021.12.005_bib0745","doi-asserted-by":"crossref","DOI":"10.1177\/2329048X20979253","article-title":"Interleukin-6 blockade with tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)","volume":"7","author":"Stredny","year":"2020","journal-title":"Child Neurol Open"},{"key":"10.1016\/j.neurol.2021.12.005_bib0750","first-page":"824","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an Institutional Cohort Study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.neurol.2021.12.005_bib0755","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fneur.2017.00111","article-title":"New-onset refractory status epilepticus with claustrum damage: definition of the clinical and neuroimaging features","volume":"8","author":"Meletti","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0760","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000341143","article-title":"Antibody-mediated status epilepticus: a retrospective multicenter survey","volume":"68","author":"Holzer","year":"2012","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neurol.2021.12.005_bib0765","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1684\/epd.2019.1104","article-title":"Avoiding anaesthetics after multiple failed drug-induced comas: an unorthodox approach to management of new-onset refractory status epilepticus (NORSE)","volume":"21","author":"Eaton","year":"2019","journal-title":"Epileptic Disord Int Epilepsy J Videotape"},{"key":"10.1016\/j.neurol.2021.12.005_bib0770","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.mayocp.2018.12.004","article-title":"Communication challenges: a spotlight on new-onset refractory status epilepticus","volume":"94","author":"Gofton","year":"2019","journal-title":"Mayo Clin Proc"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721007918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721007918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:37Z","timestamp":1758519937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378721007918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":75,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0035378721007918"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.12.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New onset refractory status epilepticus: State of the art","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}